Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
2019 was a standout year for biopharma, anchored by strong fourth quarter markets and dealmaking.
Following a difficult end to 2018, the biopharma industry recovered impressively to achieve an excellent 2019. A fourth-quarter surge on the stock markets meant that many companies ended the year on a high note, as investors flocked to drug developers of all sizes.
For medtech, the rises seen in big- and mid-cap share prices outpaced even the best in biopharma. However, medtech experienced a very different Q4, with IPO numbers declining and fewer FDA approvals, making it a mixed year for the sector.
Download your copy of Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review to understand which areas are thriving and which are struggling, as well as what this means for 2020.